Sonnet BioTherapeutics Holdings Inc. develops immunotherapeutic biologic drugs for oncology using its FHAB Fully Human Albumin-Binding platform. The platform uses a fully human single-chain antibody fragment designed to bind human serum albumin and transport large-molecule therapies toward tumor and lymphatic tissue, supporting constructs that include cytokines, peptides, antibodies and vaccines.
Company news centers on clinical and regulatory updates for targeted oncology programs, including SON-1010 or IL-12-FHAB in solid tumors and platinum-resistant ovarian cancer, as well as scientific conference presentations, shareholder voting matters, financing activity, capital-structure disclosures and governance developments.
Sonnet BioTherapeutics Holdings (NASDAQ:SONN) reported significant advancements in its drug pipeline and announced a successful warrant repricing and exchange, generating gross proceeds of $10.5 million. During Q1 2020, Sonnet completed preclinical studies showing promising results in tumor reduction with its FHAB-derived drug candidates. The company is negotiating a licensing deal for its IL-6 assets for diabetic neuropathy, potentially earning $500,000 upfront and up to $36 million in milestone payments. As of June 30, 2020, Sonnet has $3.1 million cash on hand.